Rayyan Zafar & Jaime Brambila Medi cannabis & psychedelics as adjunctive treatment in breast cancer

Подробнее о видео

Please support our work and enable us to continue to share these talks for free by donating at www.paypal.me/

Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer.

ABSTRACT
A 49-year-old woman was diagnosed with an ER + , PR-, HER2 + , BRCA- invasive ductal carcinoma which progressed metastatically to include bone, liver, and lymph node involvement. Standardised care included a 26-month treatment period with targeted chemotherapy and a ketogenic diet. The patient also began a course of cannabinoid-based therapy, consisting initially of a titrated high-dose protocol of mixed cannabidiol (CBD) and d9-tetrahydrocannabinol (THC) chemotypes, as well as psilocybin-assisted psychotherapy at macro and intermittent micro-doses. At the end of the five-month treatment period PET/CT investigations revealed no evidence of metastatic disease and chemotherapy was withdrawn. A one year follow up CT investigation concluded no evidence of residual or recurrent disease.

A recurrence of disease was noted at 18 months follow up. Over these 18 months the cannabis regimen was titrated down to 60% of the initial protocol. This was subsequently increased to the initial dosing protocol following detection of recurrent disease and this titration occurred over a 10-month period where it remained stable. 16 months following the detection of recurrence of disease, favourable results were observed in the patient with evidence of receding cancer progression. Over the last 15 years there has been a considerable body of in-vitro and in-vivo evidence supporting the anti-neoplastic properties of cannabinoids and more recently psychedelics. Indeed, growing anecdotal and real-world evidence is reported of the therapeutic effect of cannabinoids and psychedelics in reducing both tumour proliferation and aiding as a palliative medicine to treat pain and psychological distress associated with cancer and chemotherapy. The data presented here indicate the potential therapeutic utility of such adjunctive pharmacological interventions in an individual with metastatic breast cancer.

BIOGRAPHY
Rayyan has previously completed undergraduate studies in BSc Biomedical Sciences at Newcastle University and an MSc in Clinical Neuropsychiatry from Kings College London, IOPPN. He is currently undertaking his Ph.D. at Imperial College after being awarded the Medical Research Council Doctoral Training 3.5 year fellowship (MRC DTP).

As a member of the Centre for Psychedelic Research and Neuropsychopharmacology group, he is working with Prof David Nutt and Dr David Erritzoe complete a series of multimodal neuroimaging investigations in addicted populations and to investigate the role of psychedelics in treating these populations. He also works for the charity Drug Science conducting scientific, healthcare and policy research in the field of medical psychedelics and medical cannabis

Jaime Brambila:
A respected endocannabinologist, Jaime is deeply versed in endocannaboinoid system physiology, cannabis pharmacology, and dosing. Jaime began his foray into cannabis research in 2014 while searching for alternative treatments for his mother who has Lupus, and his father-in-law, who had COPD and congestive heart failure. His practice is to coach and educate patients and physicians about the clinical use of cannabinoids and other plant-based medicines. The principal aspects of our mission are to democratize plant-based medicine and democratize the science, taking the complex pharmacological information and breaking it down so everyone can understand the therapeutic potential.